Arbor Pharmaceuticals, LLC and Debiopharm International SA Announce Commercial Availability of Triptodur(TM), Triptoreli

About Debiopharm International SA 

Part of Debiopharm Group(TM) - a Swiss-headquartered global biopharmaceutical group including five companies active in the life science areas of drug development, GMP manufacturing of proprietary drugs, diagnostic tools and investment management - Debiopharm International SA is focused on the development of prescription drugs that target unmet medical needs. The company in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide.

For more information, please visit www.debiopharm.com [http://www.debiopharm.com ].

We are on Twitter. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews.

About Arbor Pharmaceuticals LLC 

Arbor Pharmaceuticals, headquartered in Atlanta, Georgia, is a specialty pharmaceutical company currently focused on the cardiovascular, neurology, hospital and pediatric markets as well as generics through its Wilshire division. The company has approximately 750 employees, with over 625 sales professionals that promote its products to hospitals and physicians. In addition to its extensive pipeline, the company continues to actively pursue growth through acquisition or licensing of marketed or late-stage development products. Arbor currently markets twenty-two approved NDA and ANDA products, and, along with Wilshire, has over forty products in development. For more information regarding Arbor Pharmaceuticals or any of its products, visit www.arborpharma.com [http://www.arborpharma.com ] or send email inquiries to info@arborpharma.com

References

1. Partsch CJ, Sippell WG. Treatment of central precocious puberty. Best Pract Res Clin Endocrinol Metab.2002;16:165-189.

2. Muir A. Precocious puberty. Pediatr Rev. 2006;27:373-381.

3. Carel JC, Leger J. Clinical practice. Precocious puberty. N Engl J Med. 2008;358(22) :2366-2377.

4. Carel JC, Lahlou N, Roger M & Chaussain JL. Precocious puberty and statural growth. Human Reproduction Update. 2004;10:135-147.

5. Precocious puberty. Mayo Clinic Web site. http://www.mayoclinic.org/diseases-conditions/precocious-pub... . Accessed June 21, 2017.

6. Mendle, J., et al. Detrimental Psychological Outcomes Associated with Early Pubertal Timing in Adolescent Girls. Dev Rev. 2007; 27(2): 151-171.

7. Johansson T & Ritzen EM. Very long-term follow-up of girls with early and late menarche. Endocrine Development. 2005;8:126-136.

8. Triptodur [package insert]. Atlanta, GA: Arbor Pharmaceuticals, LLC. http://arborpharma.com/docs/TriptodurFul...

9. Faqua JS. Treatment and outcomes of precocious puberty: an update. J Clin Endocrinol Metab. 2013;98(6):2198-207.

10. Klein K, et al. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty. J Pediatr Endocrinol Metab. 2016;29(11):1241-1248.

11. Antoniazzi F, Zamboni G. Central precocious puberty: current treatment options. Paediatr Drugs. 2004;6:211-231.

12. Early Puberty. Lurie Children's Web site.  https://www.luriechildrens.org/en-us/care-services/condition... .  Accessed June 21, 2017.

PP--TRIP-US-0056

Arbor Pharmaceuticals, LLC Contact Melissa Bond Spectrum Science Communications mbond@spectrumscience.com Tel: +1-212-468-5340 Debiopharm International SA Contact Christelle von Bueren Communication Coordinator christelle.vonburen@debiopharm.com Tel: +41(0)21-321-01-11